Capricorn Healthtech Fund II kicks off with first investment in Aspect Analytics’ € 10 million Series A round

Aspect Analytics, a leading provider of software for spatial biology data analysis, today announced the successful closing of an oversubscribed 10 million euro Series A funding round. The investment will accelerate the company’s international expansion, support continued innovation, and reinforce its position as the leader in spatial multi-omic data integration and large-scale research collaborations.

The announcement coincides with a strategic leadership transition. Marc Claesen, co-founder and former CEO, will assume the role of Chief Technology Officer, leveraging his deep expertise in spatial biology, machine learning, and artificial intelligence to drive the company’s AI-powered analytical capabilities. Steven Verhoeven will take on the role of Chief Executive Officer, bringing extensive experience in scaling VC- and PE-backed life sciences and diagnostics companies globally.

A Unique Approach to Spatial Biology

Aspect Analytics provides a patented software platform that enables researchers to integrate data from multiple spatial technologies, delivering true multi-omics insights. The Weave platform is uniquely capable of analyzing data at scale and deciphering complex multicellular environments, providing pharmaceutical and academic researchers with critical insights to uncover novel targets, unravel drug mechanisms of action, and optimize clinical trial cohorts.

Marc Claesen, CTO of Aspect Analytics:

• Spatial biology is generating massive amounts of data but turning it into actionable insights is where the true value lies. Our high-end data analysis services and Weave platform remove critical barriers in spatial biology data analysis, management and visualization. This enables researchers to collaboratively integrate and interact with diverse datasets, analyze multicellular systems at scale, and leverage advanced AI/ML methods to uncover insights that were previously out of reach.”

Fueling Growth and Global Expansion

The Series A funding will support Aspect Analytics’ international expansion, continued product innovation, and delivery of unique, industry-leading capabilities to its customers. The round was led by PMV and Capricorn Partners, through their Capricorn Healthtech Fund II, alongside existing shareholders and management. Existing investors include Heran Partners, Gemma Frisius Fund and KU Leuven.

Steven Verhoeven, CEO of Aspect Analytics:

• As we enter this next chapter, our goal is simple: scaling Aspect Analytics’ impact in drug discovery. With this investment, Marc driving our technology, and our team’s expertise, we’re ready to expand globally, empower researchers to unlock breakthrough discoveries, and set the standard in spatial biology data analysis.”

Katrin Geysken, Managing Partner of Capricorn Partners:

• We’re excited to announce Aspect Analytics as our first investment from the Capricorn Healhtech Fund II with the mission to pave they way for individualized treatments.”